Nycomed snags Bruker contrast injector

Article

The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology,

The increasing speed of MRI and CT systems and their expanding vascular indications have made precision and reproducibility paramount considerations in contrast-enhanced studies. In mid-January, Nycomed Amersham locked in access to this technology, acquiring a sophisticated power injector system from Swiss-based manufacturer Bruker. Called Tomoject, this pump injector provides the constant and reliable flow of contrast media necessary for ultrafast imaging, including contrast-enhanced angiography, tumor diagnostics, organ perfusion, and incremental body imaging. Tomoject is currently marketed in Europe and other international venues. The manufacturing site will remain Zurich.

Recent Videos
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Related Content
© 2025 MJH Life Sciences

All rights reserved.